Innovation is gaining momentum as emerging leaders secure funding and forge strategic deals to bring next-gen solutions to market. Fresh funding and strategic deals are turning prototypes into real-world solutions. From surgical AI to spine innovation and wearable neuromodulation, these moves are reshaping how care is delivered.
Microbot Medical closes up to $92.2 million in financing
The company brought in about $25.2 million from the first closing. $1.2 million from the second and $2.8 million from the third. Additional gross proceeds from short-term investment options, if fully exercised, would reach approximately $63 million.
It plans to use proceeds to continue development, commercialization and regulatory efforts for its Liberty robotic system.
CEO, Chair and President Harel Gadot
Last week’s tracker: QT Imaging, DermaSensor & more
AtaCor raises $75M to support extravascular defibrillator
AtaCor Medical entered a financing worth up to $75 million to support its U.S. FDA pivotal study.
The study evaluates the company’s parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system. The EV-ICD aims to treat life-threatening ventricular tachyarrhythmias. Funds add to $28 million brought in last year.
CEO Rick Sanghera
Jupiter Endovascular raises more than $40M in oversubscribed Series B
Sonder Capital led the financing, while Senvest Management, LB Investment and a new strategic corporate investor participated.
The company plans to use proceeds to complete its ongoing SPIRARE II pivotal clinical trial. Funds could also go toward preparing for commercialization and developing new clinical applications for its transforming fixation (TFX) platform technology.
CEO Carl St. Bernard
Spineart raises CHF 25M to boost global expansion and spine surgery innovation
The round was supported by long-term partners Gimv and EGS Beteiligungen, reaffirming investor confidence in the company’s trajectory.
The fresh funding will enable Spineart to scale its presence across Europe and the United States, while further developing its pipeline of implants, navigation tools, and robotics.
CEO Jerome Trividic
Oath Surgical raises $24 million for surgical AI ecosystem
FPV Ventures led the financing round. The company also received a new investment from McKesson Ventures, according to a LinkedIn post from Oath CEO Oliver Keown.
The funding will accelerate development and expansion of the company’s AI-based surgical centers, which will be powered by its proprietary AI-driven surgical operating system OathOS.
CEO Oliver Keown
Neuronoff closes oversubscribed $4.5M round to launch Injectrode platform
The company announced the closure of an oversubscribed $4.5 million financing round to advance its Injectrode® platform toward FDA clearance and commercial launch.
The funding supports scaling production to 1,000 units annually and preparing for a limited U.S. launch in 2026 targeting interventional pain physicians, spinal surgeons, podiatrists, and other specialties treating chronic pain.
CEO Manfred Franke
Galway’s Fortis Medical gets €2.1m DTIF award for post-stroke wearable
Fortis Medical Devices has secured €2.1m from the Irish Government’s Disruptive Technologies Innovation Fund to develop a wearable device to help people suffering from gait problems after stroke.
The University of Galway spin-out will lead a consortium that includes RCSI University of Medicine and Health Sciences and Smart Electronics to further develop their CueStim-Stroke device.
CEO Thomas Gutierrez
RevBio receives a $2.2 million Phase II NIH grant
RevBio has been awarded a $2.2 million Phase II Small Business Innovation Research grant from the National Institute on Aging, part of the National Institutes of Health.
It will enable the company to complete preclinical product testing which is a key development step for obtaining approval from the U.S. Food & Drug Administration to initiate a human clinical trial.
Founder and CEO Brian Hess
Askel Healthcare has closed its latest crowdfunding round
Askel Healthcare announced it closed its latest crowdfunding round. The company shared that 625 investors participated – both new and returning, bringing in €1.76 million.
The funding will help it advance the Class III implant through the clinical phase.
CEO Virpi Muhonen
Panda Surgical raises $1.3M for handheld neurosurgical robot
The company announced the closing of a strategic investment worth £1 million ($1.34 million) to support its handheld robotic system. The funds support the Panda Surgical system, a novel handheld robotic platform.
Oxford Investment Consultants led the round. New Wave Ventures also participated, with UCL Business joining alongside U.S. and European neurosurgeons and operators.
Co-founder and CEO Manios Dimitrakakis
